Violeta V. Valcheva
Bulgaria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host-Directed Strategies.
Journal: Medicinal research reviews
Published: December 09, 2025
Genomic Insight into Primary Adaptation of Mycobacterium tuberculosis to Aroylhydrazones and Nitrofuroylamides In Vitro.
Journal: Antibiotics (Basel, Switzerland)
Published: February 01, 2025
Adaptation of Mycobacterium tuberculosis to a New Aroylhydrazone Derivative In Vitro and Possible Role of Rv3755c Gene.
Journal: Bulletin of experimental biology and medicine
Published: December 02, 2024
Antimycobacterial Activity of Essential Oils from Bulgarian Rosa Species Against Phylogenomically Different Mycobacterium tuberculosis Strains.
Journal: Pharmaceutics
Published: August 08, 2024
Evaluation of Acute and Sub-Acute Toxicity, Oxidative Stress and Molecular Docking of Two Nitrofuranyl Amides as Promising Anti-Tuberculosis Agents.
Journal: Biomolecules
Published: July 03, 2023
Insight into pathogenomics and phylogeography of hypervirulent and highly-lethal Mycobacterium tuberculosis strain cluster.
Journal: BMC infectious diseases
Published: March 11, 2023
Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide-Hydrazone and Thiadiazole Derivatives Targeting InhA.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 28, 2023
First Insight into Diversity of Minisatellite Loci in Mycobacterium bovis/M. caprae in Bulgaria.
Journal: Diagnostics (Basel, Switzerland)
Published: January 20, 2023
In Vivo Toxicity, Redox-Modulating Capacity and Intestinal Permeability of Novel Aroylhydrazone Derivatives as Anti-Tuberculosis Agents.
Journal: Pharmaceutics
Published: October 28, 2022
Molecular Insight into Mycobacterium tuberculosis Resistance to Nitrofuranyl Amides Gained through Metagenomics-like Analysis of Spontaneous Mutants.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 12, 2022
Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives.
Journal: Antibiotics (Basel, Switzerland)
Published: March 16, 2022
Last Updated: 09/26/2026